O
RAPT

OrbiMed’s RAPT Therapeutics RAPT Stock Holding History

OrbiMed’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,642,891
Closed -$55.6M – 125
2025
Q4 		$55.6M Buy
1,642,891
+556,273
+51% +$17.3M 1.14% 26
2025
Q3 		$28M Sell
1,086,618
-555,288
-34% -$7.27M 0.66% 44
2025
Q2 		$13.1M Sell
1,641,906
-2
-0% -$15 0.33% 52
2025
Q1 		$16M Hold
1,641,908
– – 0.38% 49
2024
Q4 		$20.8M Buy
+1,641,908
New +$20.9M 0.43% 53
2024
Q1 		– Sell
-35,177
Closed -$6.99M – 124
2023
Q4 		$6.99M Sell
35,177
-120,441
-77% -$14.9M 0.14% 85
2023
Q3 		$20.7M Sell
155,618
-766
-0.5% -$125K 0.44% 63
2023
Q2 		$23.4M Hold
156,384
– – 0.42% 66
2023
Q1 		$23M Hold
156,384
– – 0.45% 62
2022
Q4 		$24.8M Hold
156,384
– – 0.47% 61
2022
Q3 		$30.1K Buy
156,384
+48,084
+44% +$9.1M 0.56% 58
2022
Q2 		$15.8K Buy
108,300
+63,137
+140% +$8.41M 0.29% 73
2022
Q1 		$7.95M Buy
45,163
+18,038
+66% +$3.41M 0.13% 108
2021
Q4 		$7.97M Buy
+27,125
New +$7.25M 0.1% 121

OrbiMed's RAPT Position: Q1 2026 in Review

OrbiMed sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 1,642,891 shares — an estimated $55.6M sold.

OrbiMed first reported a position in RAPT in Q4 2021 and held it in 14 quarters. The position peaked at $55.6M in Q4 2025. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • OrbiMed reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 1,642,891 RAPT Therapeutics shares in Q1 2026, an estimated $55.6M.
  • OrbiMed first reported a position in RAPT Therapeutics in Q4 2021 and held it in 14 quarters.
  • OrbiMed's RAPT Therapeutics position peaked at $55.6M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.